Implied Volatility Surging for Ardent Health Stock Options
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.

Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.23 · Revenue $1.60B · 4 analysts
Est. EPS $0.33 · Revenue $1.63B · 4 analysts
Est. EPS $0.96 · Revenue $6.46B · 6 analysts
Est. EPS $0.28 · Revenue $1.66B · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $6.3B | +6.0% | +1.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $135.8M | -35.4% | -57.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +97.5% | +18.0% | -61.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +5.1% | -24.3% | -47.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +2.1% | -39.1% | -58.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $258.6M | +102.8% | +279.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +4.1% | +91.3% | +276.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 134.3% | -33.4% | +27.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.97x | +1.5% | -0.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $5.3B | +6.7% | +0.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.96 vs 1.05 | -8.4% | 0.12 vs 0.23 | -48.4% |
| Revenue Surprise | $6.3B vs $6.4B | -0.5% | $1.6B vs $1.6B | +1.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Caspers Dave | director, officer: CEO and President | Common Stock | A | 103,653 | — |
| Jun 5, 2026 | DeMichiei Robert | director | Common Stock | A | 11,260 | $8.73 |
| Jun 5, 2026 | LUMSDAINE ALFRED | officer: Chief Financial Officer | Common Stock | A | 10,000 | $8.81 |
| Apr 1, 2026 | Bulgarelli Peter J. | director | Common Stock | A | 14,231 | — |
| Apr 1, 2026 | Havdala Ellen | director | Common Stock | A | 14,231 | — |
Operator: Hello, and thank you for standing by. My name is Lacy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ardent Health Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Thank you. I would now like to turn the call over to Dave Styblo, Senior Vice President of Investor Relations. You may go ahead. David Styblo: Thank you, operator, and welcome to Ardent Health's Second Quarter 2026 Earnings Conference Call. Joining me today is Ardent's President and Chief Executive Officer, Dave Caspers; and Chief Financial Officer, Alfred Lumsdaine. Dave and Alfred will provide prepared remarks, and then we will open the line to questions. Before I turn the call over to Dave, I want to remind everyone that today's discussion contains forward-looking statements about future business and financial expectations. Actual results may differ significantly from those projected in today's forward-looking statements due to various risks and uncertainties, including the risks described in our periodic reports filed with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to update our forward-looking statements. Further, this call will include the discussion of certain non-GAAP financial measures, including adjusted EBITDA. Reconciliation of these measures to the closest GAAP financial measure is included in our quarterly earnings press release and supplemental earnings presentation, which were both issued yesterday evening after the market closed and are available at ardentthealth.com. With that, I'll turn the call over to Dave. David Caspers: Thank you, and good morning. I want to begin by thanking our 25,000 team members for the way they continue to adapt, improve how we operate and deliver high-quality care to our patients and communities we serve. To frame today's discussion, I'll focus my comments on 3 areas: first, where we stand, including the strength of our current platform; second, where we're going, including my priorities and the opportunities ahead; and third, what you can expect from me. Let's start with where we stand. The Ardent platform is built on a strong foundation with clear opportunities to improve our performance. With 30 hospitals and over 280 sites of care, attractive markets growing 2 to 3x faster than the U.S. average and strong joint venture partners, we are well positioned to capture market share. Over the past 2 years, we have broadened our access points and strengthened partnerships by acquiring and/or building over 25 urgent care and ASC facilities. These investments expand our ability to care for patients across the most appropriate care setting while also targeting volume growth. In addition, strategic partnerships, specifically with Ensemble and Epic, are strengthening our revenue cycle and clinical capabilities. In short, we are well positioned, but there is more work ahead. Since transitioning into this role, I've …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
David Caspers | President, Chief Executive Officer & Director | USD 1,290,846 | Male | 1971 | Active |
Alfred Lumsdaine | Chief Financial Officer | USD 714,235 | Male | 1965 | Active |
Stephen Christopher Petrovich | Executive Vice President, Chief Legal Officer & Secretary | USD 596,241 | Male | 1967 | Active |
Jason Ehrlinspiel | Chief Compliance Officer | — | Male | 1971 | Active |
Caitlin Franklin | Chief Administrative Officer | — | Female | — | Active |
Donald Baker | Regional President of Lone Star Region | — | Male | 1971 | Active |
Kevin J. Gross FACHE | Regional President of Oklahoma Region | — | Male | 1956 | Active |
Lonnie Garrison | Chief Technology Officer | — | Male | — | Active |
Frank J. Campbell | Chief Medical Officer | — | — | 1969 | Active |
David Anthony Styblo | Senior Vice President of Investor Relations | — | Male | — | Active |
David Byers | Senior Vice President & Chief Accounting Officer | — | Male | 1982 | Active |
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.

BRENTWOOD, Tenn. & TULSA, Okla.--(BUSINESS WIRE)--Oklahoma Heart Institute (OHI), part of Hillcrest HealthCare System and Ardent Health (NYSE: ARDT), is now the only site in Oklahoma and the surrounding region participating in several leading national cardiovascular trials – and recently became the first in the United States to use the next-generation Supira percutaneous left ventricular assist device (pVAD) as part of the SUPPORT II clinical trial. Through this research, OHI is expanding acces.

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

Ardent Health NYSE: ARDT reported second-quarter revenue of $1.62 billion and adjusted EBITDA of $115 million, as management said cost controls, a favorable payer contract renewal and strong cash flow helped offset weaker-than-expected volumes.

Ardent Health, Inc. (ARDT) Q2 2026 Earnings Call Transcript
